Access to Genetic Testing in Underserved Patients With Cancer

Recruiting now · Not applicable

Conditions studied: Breast Carcinoma, Male Breast Carcinoma, Malignant Solid Neoplasm, Metastatic Prostate Carcinoma, Ovarian Carcinoma, Pancreatic Exocrine Neoplasm, Stage IVB Prostate Cancer American Joint Committee on Cancer v8, Triple-Negative Breast Carcinoma

In brief

This study compares the experiences of people who receive information about genetic testing from a computer-generated character to patients who receive information from a human genetics healthcare provider. Patients with cancer are increasingly recommended for genetic testing as standard of care. Multiple factors contribute to low usage of genetic testing but for many patients the lack of access to genetic counseling and testing is an important and flexible factor. Lack of access is especially relevant to racial/ethnic minority patients and those living in non-metropolitan rural settings who are frequently cared for at safety-net hospitals with limited genetics services. Alternative delivery models are necessary to improve rates of access to genetic testing in patients with cancer. Health information technology is under used by genetics providers. A patient-facing relational agent (PERLA) will provide pre-test genetics education in both English and Spanish across two clinical settings to facilitate more timely access to genetic testing. Using the PERLA intervention may help researchers learn different ways to provide education about genetic testing to patients with cancer compared to usual care.

Key facts

Study ID

NCT06422455

Run by

University of Southern California

People needed

800

Starts

2023-10-24

Expected to finish

2028-10-24

Last updated by the study team

2026-03-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age > 18 years old
• Diagnosed with least one of the following:
• Epithelial ovarian cancer
• Exocrine pancreatic cancer
• Metastatic or high or very high-risk prostate cancer
• Breast cancer at or before age 50
• Bilateral breast cancer
• Triple negative breast cancer
• Male breast cancer OR
• Healthcare provider who treats patients with any of the above types of cancer
• Able to read and write in English or Spanish
• Able to provide informed consent

You may not qualify if…

• Patients who cannot provide informed consent
• Patients who cannot see, read, or write
• Patients who have the cancer and clinical characteristics defined in the inclusion criteria, but who do not speak English or Spanish
• Patients with none of the listed cancer diagnoses and clinical characteristics
• Healthcare provider who do not treats cancer patients

Where it is running

• USC / Norris Comprehensive Cancer Center — Los Angeles, California, United States (enrolling)
• University of Rochester — Rochester, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.